Grifols, SA
GRF.P
ISIN ES0171996095 / Valor 30689500
Grifols, SA
UMushroom community rating:
About company
Grifols, SA is a global healthcare company that specializes in the development, production, and distribution of plasma-derived medicines, other biopharmaceuticals, and transfusion medicine solutions. The company plays a critical role in the healthcare sector by providing essential products that support the treatment of various medical conditions and diseases. Grifols' offerings include innovative technologies and products for blood typing, specifically the agglutination technique that uses gel as a reagent for determining blood groups and ensuring transfusion compatibility. This technique is notable for its use of cards with 6 to 8 wells filled with gel for testing purposes. Additionally, Grifols is involved in the production of organic compounds, including those belonging to the amino acid group, which are essential for various bodily functions and are found in some foods of animal origin. The company also prepares medicines for intravenous use, which can be administered through reconstitution or by mixing with existing solutions for fluid therapy. Grifols' commitment to advancing healthcare solutions underscores its position as a leader in the pharmaceutical and biotechnology industries, significantly impacting patient care worldwide.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (11.10.2025):
Grifols, SA reported strong financial performance in Q1 2025, showcasing significant growth in revenues, adjusted EBITDA, and free cash flow. The company reaffirmed its guidance for the full year 2025, indicating sustained momentum and strategic execution.
Revenue Growth
Revenues increased by 7.4% constant currency (cc) to EUR 1,786 million, reflecting robust demand and effective market strategies.
Adjusted EBITDA Improvement
Adjusted EBITDA rose by 14.2% cc to EUR 400 million, demonstrating enhanced operational efficiency and profitability.
Enhanced Free Cash Flow
Free cash flow improved by EUR 209 million compared to the same period last year, strengthening the company's financial flexibility.
Full-Year Guidance Reaffirmed
Grifols reaffirmed its financial guidance for FY 2025, highlighting its commitment to consistent growth and strategic objectives throughout the year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2249 M
Market cap (USD)
90,511
Daily traded volume (Shares)
7.17 / 6.98
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
